Actively Recruiting
Phase I Trial Evaluating Blinatumomab and Low-Dose Donor Lymphocyte Infusion as Maintenance Therapy After Stem Cell Transplant in High-Risk Acute B-Lymphoblastic Leukemia
Led by Liping Dou · Updated on 2026-07-01
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying high-risk acute B-lymphoblastic leukemia B-ALL patients who have undergone allogeneic hematopoietic stem cell transplantation allo-HSCT. This single-center, prospective Phase I trial aims to evaluate the safety and therapeutic effects of combining blinatumomab with low-dose donor lymphocyte infusion DLI as maintenance therapy. The goal is to improve long-term survival outcomes in these patients. Participants receive blinatumomab in a dosing schedule of 9 micrograms per day for the first 7 days, followed by 28 micrograms per day from days 8 to 14, combined with low-dose DLI CD3 cells at 1x105kg. The first treatment cycle begins within the first three months after transplant, with additional cycles at about 6, 9, and 12 months post-transplant. Premedication with dexamethasone is given before each cycle to help manage side effects. During the study, participants undergo regular assessments including bone marrow flow cytometry to confirm minimal residual disease MRD status and monitoring for graft-versus-host disease GVHD. Researchers track outcomes such as one-year progression-free survival, acute and chronic GVHD rates, nonrelapse mortality, and overall survival. The trial follows participants for at least one year after transplantation to evaluate these measures and monitor safety and treatment effects.
CONDITIONS
Brief Title
Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
Research Team
L
Lu Wang
L
Liping Dou, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here